The presentation of initial Phase 1/1b data is a binary catalyst for this micro-cap biotech. If the data show favorable safety and early efficacy signals, the stock could re-rate significantly; if results are weak or inconclusive, downside risk is substantial given the single-asset profile. Monitor for the conference date and any pre-release abstracts.
Price Chart
Executive Summary
Pasithea Therapeutics announced it will present initial clinical data from its ongoing Phase 1/1b trial of PAS-004 in adult NF1 patients at the 2026 European NF Conference. This is a data-readout catalyst for a single-asset, early-stage biotech with an $18M market cap, but no actual results or efficacy numbers were disclosed in the press release.
Key Facts
- Pasithea to present initial PAS-004 Phase 1/1b clinical data in adult NF1 patients at the 2026 European NF Conference.
- PAS-004 is the company's lead candidate; no prior clinical data or efficacy results have been disclosed.
- Market cap is $18M; the company is pre-revenue with no approved products.
Financial Impact
No financial data disclosed; event is a data presentation catalyst with binary outcome risk.
Risk Factors
- Phase 1/1b data may show insufficient efficacy or safety concerns, leading to stock decline.
- Single-asset company with no approved products; failure of PAS-004 would be value-destructive.
- No timeline or specific data points provided; uncertainty around the magnitude of the disclosure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3360920 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 5w ago | 8-K | $0.5067 $0.4101 | ▼ −19.06% | ▼ −20.27% | $0.3999 (−21.08%) |
Sep 14, 2026 6w ago | Press Release | $0.5100 $0.4475 | ▼ −12.25% | ▼ −14.52% | $0.3999 (−21.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers